| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8740791 | Journal of Infection and Chemotherapy | 2017 | 4 Pages |
Abstract
Our survey revealed that 22.5% subjects experienced any adverse events due to oseltamivir. And the regimen showed low compliance than we expected. On the other hands, zanamivir showed high adherence with lower incidence of adverse events.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Hideo Kato, Mao Hagihara, Yukiko Kato, Ai Kurumiya, Tomoko Takahashi, Miki Sakata, Naoya Nishiyama, Nobuhiro Asai, Yusuke Koizumi, Tatsuro Furui, Yuka Yamagishi, Hiroshige Mikamo,